Literature DB >> 20675674

EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy.

Luigi Padeletti1, David O Arnar, Lorenzo Boncinelli, Johannes Brachman, John A Camm, Jean Claude Daubert, Sarah K Hassam, Sarah Kassam, Luc Deliens, Michael Glikson, David Hayes, Carsten Israel, Rachel Lampert, Trudie Lobban, Pekka Raatikainen, Gil Siegal, Panos Vardas, Paulus Kirchhof, Rüdiger Becker, Francisco Cosio, Peter Loh, Stuart Cobbe, Andrew Grace, John Morgan.   

Abstract

The purpose of this Consensus Statement is to focus on implantable cardioverter-defibrillator (ICD) deactivation in patients with irreversible or terminal illness. This statement summarizes the opinions of the Task Force members, convened by the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS), based on ethical and legal principles, as well as their own clinical, scientific, and technical experience. It is directed to all healthcare professionals who treat patients with implanted ICDs, nearing end of life, in order to improve the patient dying process. This statement is not intended to recommend or promote device deactivation. Rather, the ultimate judgement regarding this procedure must be made by the patient (or in special conditions by his/her legal representative) after careful communication about the deactivation's consequences, respecting his/her autonomy and clarifying that he/she has a legal and ethical right to refuse it. Obviously, the physician asked to deactivate the ICD and the industry representative asked to assist can conscientiously object to and refuse to perform device deactivation.

Entities:  

Mesh:

Year:  2010        PMID: 20675674     DOI: 10.1093/europace/euq275

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  38 in total

1.  Current pacemaker and defibrillator therapy. In the context of the end of life.

Authors:  Jan Gaertner; Steffen Simon; Raymond Voltz
Journal:  Dtsch Arztebl Int       Date:  2011-10-07       Impact factor: 5.594

2.  Improving Communication in Heart Failure Patient Care.

Authors:  Nathan E Goldstein; Harriet Mather; Karen McKendrick; Laura P Gelfman; Mathew D Hutchinson; Rachel Lampert; Hannah I Lipman; Daniel D Matlock; Jacob J Strand; Keith M Swetz; Jill Kalman; Jean S Kutner; Sean Pinney; R Sean Morrison
Journal:  J Am Coll Cardiol       Date:  2019-10-01       Impact factor: 24.094

3.  A study to improve communication between clinicians and patients with advanced heart failure: methods and challenges behind the working to improve discussions about defibrillator management trial.

Authors:  Nathan E Goldstein; Jill Kalman; Jean S Kutner; Erik K Fromme; Mathew D Hutchinson; Hannah I Lipman; Daniel D Matlock; Keith M Swetz; Rachel Lampert; Omarys Herasme; R Sean Morrison
Journal:  J Pain Symptom Manage       Date:  2014-04-21       Impact factor: 3.612

4.  [Implantable cardioverter-defibrillator at the end of life].

Authors:  D Pfeiffer; A Hagendorff; C Kühne; S Reinhardt; N Klein
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

Review 5.  Effective communication and ethical consent in decisions related to ICDs.

Authors:  Alexander M Clark; Tiny Jaarsma; Patricia Strachan; Patricia M Davidson; Megan Jerke; James M Beattie; Amanda S Duncan; Chantal F Ski; David R Thompson
Journal:  Nat Rev Cardiol       Date:  2011-07-26       Impact factor: 32.419

Review 6.  [Choosing wisely at the end of life : Recommendations of the German Society for Palliative Medicine (DGP)].

Authors:  B Alt-Epping
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

7.  The prevalence and contents of advance directives in patients with pacemakers.

Authors:  Dario Pasalic; Tanya H Tajouri; Abigale L Ottenberg; Paul S Mueller
Journal:  Pacing Clin Electrophysiol       Date:  2013-11-11       Impact factor: 1.976

Review 8.  [Ethics in intensive care and euthanasia : With respect to inactivating defibrillators at the end of life in terminally ill patients].

Authors:  H-J Trappe
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11-17       Impact factor: 0.840

Review 9.  [The chronic critically ill patient from the cardiologist's perspective].

Authors:  U Janssens; S Reith
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-04-25       Impact factor: 0.840

Review 10.  The deactivation of implantable cardioverter-defibrillators: medical, ethical, practical, and legal considerations.

Authors:  Jörg Carlsson; Norbert W Paul; Matthias Dann; Jörg Neuzner; Dietrich Pfeiffer
Journal:  Dtsch Arztebl Int       Date:  2012-08-20       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.